-transparent.png){kind=logo}
1. We investigated the role of angiotensin converting enzyme (ACE) in the cardiovascular effects of N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Tyr-p-aminobenzoate (cFP), a peptidase inhibitor selective for metalloendopeptidase (EP) E.C. 3.4.24.15. 2. In conscious rabbits, cFP (5 mg kg-1, i.v.) markedly slowed the degradation of [3H]-bradykinin, potentiated the depressor response to right atrial administration of bradykinin (10-1000 ng kg-1), and inhibited the pressor response to right atrial angiotensin I (10-100 ng kg-1). In each of these respects, the effects of cFP were indistinguishable from those of the ACE inhibitor, captopril (0.5 mg plus 10 mg kg-1h-1 i.v.). Furthermore, the effects of combined administration of cFP and captopril were indistinguishable from those of captopril alone. 3. In experimentally naive anaesthetized rats, cFP administration (9.3 mg kg-1, i.v.) was followed by a moderate but sustained fall in arterial pressure of 13 mmHg. However, in rats pretreated with bradykinin (50 micrograms kg-1) a more pronounced fall of 30 mmHg was observed. Captopril (5 mg kg-1) had similar hypotensive effects to those of cFP, and cFP had no effect when it was administered after captopril. 4. CFP displaced the binding of [125I]-351A (the p-hydroxybenzamidine derivative of lisinopril) from preparations of rat plasma ACE and solubilized lung membrane ACE (KD = 1.2 and 0.14 microM respectively), and inhibited rat plasma ACE activity (KI = 2.4 microM). Addition of phosphoramidon (10 microM), an inhibitor of a range of metalloendopeptidases, including neutral endopeptidase (E.C.3.4.24.11), markedly reduced the potency of cFP in these systems. 5. Taken together these findings suggest that the actions of cFP in vivo are attributable to inhibition of ACE rather than EP 24.15. Given that cFP is a poor inhibitor of ACE in the presence of phosphoramidon in vitro, it is likely that cFP is cleaved by a phosphoramidon-sensitive metallopeptidase in vivo to liberate N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Ala, a potent ACE inhibitor.
S E Telford, and
A I Smith, and
R A Lew, and
R B Perich, and
A C Madden, and
R G Evans
March 2003,
The Journal of biological chemistry,
S E Telford, and
A I Smith, and
R A Lew, and
R B Perich, and
A C Madden, and
R G Evans
January 2006,
Biochemical and biophysical research communications,
S E Telford, and
A I Smith, and
R A Lew, and
R B Perich, and
A C Madden, and
R G Evans
January 1999,
Pediatric pulmonology. Supplement,
S E Telford, and
A I Smith, and
R A Lew, and
R B Perich, and
A C Madden, and
R G Evans
January 2005,
Cardiovascular drug reviews,
S E Telford, and
A I Smith, and
R A Lew, and
R B Perich, and
A C Madden, and
R G Evans
April 1999,
Clinical pharmacology and therapeutics,
S E Telford, and
A I Smith, and
R A Lew, and
R B Perich, and
A C Madden, and
R G Evans
September 1990,
Journal of hypertension,
S E Telford, and
A I Smith, and
R A Lew, and
R B Perich, and
A C Madden, and
R G Evans
June 2002,
Clinical pharmacology and therapeutics,
S E Telford, and
A I Smith, and
R A Lew, and
R B Perich, and
A C Madden, and
R G Evans
April 2014,
Journal of the American Society of Hypertension : JASH,
S E Telford, and
A I Smith, and
R A Lew, and
R B Perich, and
A C Madden, and
R G Evans
December 1988,
Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
S E Telford, and
A I Smith, and
R A Lew, and
R B Perich, and
A C Madden, and
R G Evans
August 1996,
Journal of enzyme inhibition,
